Regulators will also need to build up their own AI expertise to keep up, and stay close to the companies developing products, where most of the knowledge currently lies, said Thomas Inglesby, director of the Johns Hopkins Center for Health Security.

“Congress should not take their eye off some of the most serious risks, because if those risks become a major problem — either in bias or […] around life science, pandemic risks or others — I think those kinds of developments could derail or really distract the AI companies, could distract the government for a long time,” he said.